XOMA Corporation (XOMA) : During the past 4 weeks, traders have been relatively bearish on XOMA Corporation (XOMA), hence the stock is down -17.59% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -11.86% relative to the S&P 500. The 4-week change in the price of the stock is -18.04% and the stock has fallen -11.71% in the past 1 week.
The stock has recorded a 20-day Moving Average of 19.33% and the 50-Day Moving Average is 21.86%.The 200 Day SMA reached 40.21%
XOMA Corporation (NASDAQ:XOMA): After opening at $0.46, the stock dipped to an intraday low of $0.44 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $0.47 and the buying power remained strong till the end. The stock closed at $0.459 for the day, a gain of 1.93% for the day session. The total traded volume was 1,198,590. The stocks close on the previous trading day was $0.459.
XOMA Corporation (XOMA) : 3 investment research analysts covering XOMA Corporation (XOMA) have an average price target of $1.09 for the near short term. The highest target price given by the Brokerage Firm to the stock is $1 and the lowest target is $1 for the short term. Analysts expect the variance to be within $0.3 of the average price.
XOMA Corporation is engaged in the discovery and development of antibody-based therapeutics. The Companys lead product candidate, gevokizumab, is a potent, humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company has initiated three pivotal clinical trials evaluating gevokizumab for the treatment of non-infectious intermediate, posterior or pan-uveitis (NIU) and Behcets disease uveitis. The Company also has a gevokizumab Proof-of-Concept (POC) development program to identify other illness for late-stage development. These studies are known as the EYEGUARD program, which includes EYEGUARD-A (patients with active NIU), EYEGUARD-B (patients with Behcets disease uveitis outside of the United States), and EYEGUARD-C (patients with a history of NIU controlled with systemic treatment).